Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
- Registration Number
- NCT03423810
- Lead Sponsor
- University of Kansas Medical Center
- Brief Summary
The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Confirmed diagnosis of ADPKD
- estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73m^2
Exclusion Criteria
- History of systemic lupus erythematous or other rheumatologic disorder
- Baseline anti-nuclear antibody (ANA) >1:80 for females and >1:40 for males
- Blood pressure < 120/80 without anti-hypertensive
- Angina pectoris or myocardial infarction in the last 6 months
- Liver disease
- Allergy to hydralazine
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Group 1: Hydralazine Hydralazine Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
- Primary Outcome Measures
Name Time Method Change in mucin-like protocadherin (MUPCDH) Change from Baseline to Week 8 Change in polycystin-1 (PC1) Change from Baseline to Week 8
- Secondary Outcome Measures
Name Time Method Circulating methylated RASAL1 levels Change from Baseline to Week 8
Trial Locations
- Locations (1)
University of Kansas Medical Center
đşđ¸Kansas City, Kansas, United States